Special Issue

Pathophysiological and Therapeutic Perspectives of Type-1 Diabetes

Message from the Guest Editor

Knowledge on the pathogenesis and natural history of type 1 diabetes has substantially grown in the last few decades. It is an auto-immune condition characterized by the destruction of the pancreatic beta cells, leading to absolute insulin deficiency. The destruction of □-cells is triggered by genetic, environmental and immunologic factors that destroy the endocrine cells of the pancreas, leading to insulin deficiency. Furthermore, inflammation (e.g., interleukin-1 mediated) may play a significant role in islet □-cells loss in type-1 diabetes. Patients with type 1 diabetes may also, coincidentally, have pathophysiologic elements of type 2 diabetes. We invite scientists to contribute both original research articles and reviews that highlight the development of pathophysiological pathways of type-1 diabetes and current therapeutic perspectives. Both basic and translational research papers are welcome.

Guest Editor

Dr. Srinivas Nammi

Discipline of Medical Sciences, School of Science and NICM-Health Research Institute, Western Sydney University, Sydney, NSW 2751, Australia

Deadline for manuscript submissions

closed (30 September 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/si/93872

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed

mdpi.com/journal/biomedicines

MDPI

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).